|drug1153||Emotional Support Plan Wiki||0.50|
|drug1672||Interview by psychologists Wiki||0.50|
|drug787||Cognitive behavior therapy (CBT), specifically using the Facing Your Fears (FYF) curriculum Wiki||0.50|
|drug3947||placebo rinse Wiki||0.50|
|drug550||CHX0.12+CPC0.05 oral rinse (PerioAidActive Control) Wiki||0.50|
|drug549||CHLORPROMAZINE (CPZ) Wiki||0.50|
|drug958||Daily Monitoring Wiki||0.50|
|drug3140||Standard of Care (SOC) Wiki||0.22|
|D001321||Autistic Disorder NIH||0.87|
|D002659||Child Development Disorders, Pervasive NIH||0.71|
|D001289||Attention Deficit Disorder with Hyperactivity NIH||0.58|
There are 4 clinical trials
In response to the coronavirus disease 2019 (covid-19) outbreak, the home confinement of the population ordered by governments in many countries raise questions about its impact on individuals' physical and mental health in the short and longer term. In children, reduced physical activity, changes in lifestyle, disturbances in sleep patterns, lack of in-person contact with peers, poor or inadequate understanding of health risks may be risk factors of anxiety, stress, fatigue, sleep disorders (Brooks et al, 2020; Wang et al, 2020; Sprang et al, 2013). These problematic effects could be modulated by social factors (housing in urban or rural areas, availability of personal space at home, parenting stress, etc.) (Cluver et al, 2020; Liu et al, 2020).
Description: composition, home confinement, change in the environment, personal room at home, screens with internet access, parents' current professional status, teleworking, care, family concerns related to Covid-19, parenting stress, schooling, recurrent complaints.Measure: Interview of the parents : contextual data Time: Baseline
Description: related to education; related to daily family life; related to leisure, related to care (children/adolescents, parents)Measure: Interview of the children/adolescents/ parents : Experience of the confinement in general Time: Baseline
Description: related to education; related to daily family life; related to leisure, related to care (children/adolescents, parents)Measure: Interview of the children/adolescents/ parents : Experience of the confinement in general Time: 1 month
Description: related to education; related to daily family life; related to leisure, related to care (children/adolescents, parents)Measure: Interview of the children/adolescents/ parents : Experience of the confinement in general Time: 3 months
Description: Data relating to disease and management of care. Experience of the referring caregiver.Measure: Interview of the referring caregiver : data relating to disease and management of care Time: 3 months
The aims of the BIBS Study The Brain Imaging in Babies study (BIBS) aims to improve understanding of how a baby's brain develops from before birth, up until 3-4 years of age. Working with children from a variety of backgrounds and communities, the investigators use a combination of state-of-the-art diagnostic tools such as MRI scans alongside traditional behavioural assessments to capture the earliest information on infant brain development. The focus of the BIBS study MRI scanning is a safe way of producing detailed images using strong magnetic fields and radio waves. It does not use X-ray. Along with learning more about brain development in general, the investigators also try to identify features that may in future help predict whether a child will or will not develop traits of conditions such as Autism Spectrum Disorder (ASD) or Attention Deficit Hyperactivity Disorder (ADHD). Long-term, this may help target useful interventions early on, helping children who are most in need. Since COVID-19 arrived in the United Kingdom (U.K.) in 2020, the investigators have been given ethical approval to include testing for this infection in the mothers and children participating in the study. This may provide an opportunity to better understand how mother and baby respond to infections. The investigators particularly welcome mothers who have had a positive COVID-19 test during their pregnancy to join the study.
The purpose of this study is to evaluate the feasibility, acceptability and effectiveness of a brief, telehealth intervention (the Emotional Support Plan), intended to support autistic adults to cope with their negative emotions during and/or after the COVID-19 pandemic. The first objective is to develop and refine a brief telehealth-delivered treatment, the Emotional Support Plan (ESP), to help promote adults to cope during periods of acute distress, such as those experienced during the COVID-19 pandemic. The second objective is to assess the feasibility and effectiveness of the ESP to support autistic adults to implement emotion regulation strategies during periods of acute distress. The last objective is to yield preliminary data to apply for extramural grants to validate these methods to monitor and support mental health of autistic adults during key transitions (e.g., starting college).
Description: The PHQ-9, assessed weekly, is a 9-item questionnaire of psychological function over the past week with all items on a "0" (not at all) to "3" (nearly every day) scale. Higher scores equal more distress.Measure: Decreased distress on Patient Health Questionnaire (PHQ-9) Time: 8 week study period
Description: EMA (Ecological Momentary Assessment) reports of decreased distress (in ESP + daily monitoring group only). Higher scores on the item equal higher levels of distress.Measure: Decreased distress on EMA reports Time: 8 week study period
Description: The GAD-7, assessed weekly, is a 7-item questionnaire of anxiety symptoms over the past week with all items on a "0" (not at all) to "3" (nearly every day) scale. Higher scores equal more anxiety.Measure: Decreased anxiety symptoms on the Generalized Anxiety Disorder Questionnaire (GAD-7) Time: 8 week study period
Description: The ASR is a measure of adaptive functioning and psychopathology (e.g., anxiety, depression symptoms). Most of the items are on a 3 point scale including: (0) Not true, (1) Somewhat or sometimes true, and (2) Very often or often true.Measure: Adult Self Report (ASR) Time: 8 week study period
This study will examine if a virtual delivery of a group Cognitive Behavioural Therapy (CBT) program, specifically using "Facing Your Fears" (FYF) curriculum, is helpful in improving anxiety symptoms for children and youth with ASD. This study will adapt the FYF program for virtual delivery using a platform called "Zoom for Healthcare" and examine its effectiveness.
Description: The SCARED is a 38-item measure of anxious symptoms, with both child and parent versions. The parent version will be used as a primary outcome measure, administered at pre- and post-intervention.Measure: Screen for Child Anxiety Related Emotional Disorders (SCARED), Parent version Time: SCARED, Parent version will be administered at baseline (pre-intervention) and at week 12, (post-intervention) to assess change between two time points.
Description: The SCARED is a 38-item measure of anxious symptoms, with both child and parent versions. The child version will be used as a secondary outcome measure, administered at pre- and post-intervention.Measure: Screen for Child Anxiety Related Emotional Disorders (SCARED), Child version Time: SSCARED, Child version will be administered at baseline (pre-intervention) and at week 12, (post-intervention) to assess change between two time points.
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports